These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23776583)

  • 1. Cdk4 and nek2 signal binucleation and centrosome amplification in a her2+ breast cancer model.
    Harrison Pitner MK; Saavedra HI
    PLoS One; 2013; 8(6):e65971. PubMed ID: 23776583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Ras oncogene signals centrosome amplification in mammary epithelial cells through cyclin D1/Cdk4 and Nek2.
    Zeng X; Shaikh FY; Harrison MK; Adon AM; Trimboli AJ; Carroll KA; Sharma N; Timmers C; Chodosh LA; Leone G; Saavedra HI
    Oncogene; 2010 Sep; 29(36):5103-12. PubMed ID: 20581865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. E2F activators signal and maintain centrosome amplification in breast cancer cells.
    Lee MY; Moreno CS; Saavedra HI
    Mol Cell Biol; 2014 Jul; 34(14):2581-99. PubMed ID: 24797070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Silencing of E2F3 suppresses tumor growth of Her2+ breast cancer cells by restricting mitosis.
    Lee M; Oprea-Ilies G; Saavedra HI
    Oncotarget; 2015 Nov; 6(35):37316-34. PubMed ID: 26512919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Nek2 centrosome-mitotic kinase contributes to the mesenchymal state, cell invasion, and migration of triple-negative breast cancer cells.
    Rivera-Rivera Y; Marina M; Jusino S; Lee M; Velázquez JV; Chardón-Colón C; Vargas G; Padmanabhan J; Chellappan SP; Saavedra HI
    Sci Rep; 2021 Apr; 11(1):9016. PubMed ID: 33907253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nek2 and Plk4: prognostic markers, drivers of breast tumorigenesis and drug resistance.
    Marina M; Saavedra HI
    Front Biosci (Landmark Ed); 2014 Jan; 19(2):352-65. PubMed ID: 24389189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitotic perturbations induced by Nek2 overexpression require interaction with TRF1 in breast cancer cells.
    Lee J; Gollahon L
    Cell Cycle; 2013 Dec; 12(23):3599-614. PubMed ID: 24091727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells.
    Cappello P; Blaser H; Gorrini C; Lin DC; Elia AJ; Wakeham A; Haider S; Boutros PC; Mason JM; Miller NA; Youngson B; Done SJ; Mak TW
    Oncogene; 2014 May; 33(18):2375-84. PubMed ID: 23708664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells.
    Ghaleb A; Padellan M; Marchenko N
    Breast Cancer Res; 2020 Dec; 22(1):133. PubMed ID: 33267874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer.
    Hayward DG; Clarke RB; Faragher AJ; Pillai MR; Hagan IM; Fry AM
    Cancer Res; 2004 Oct; 64(20):7370-6. PubMed ID: 15492258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cdk2 and Cdk4 regulate the centrosome cycle and are critical mediators of centrosome amplification in p53-null cells.
    Adon AM; Zeng X; Harrison MK; Sannem S; Kiyokawa H; Kaldis P; Saavedra HI
    Mol Cell Biol; 2010 Feb; 30(3):694-710. PubMed ID: 19933848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of centrosome separation after DNA damage: a role for Nek2.
    Fletcher L; Cerniglia GJ; Nigg EA; Yend TJ; Muschel RJ
    Radiat Res; 2004 Aug; 162(2):128-35. PubMed ID: 15387139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nek2 kinase in chromosome instability and cancer.
    Hayward DG; Fry AM
    Cancer Lett; 2006 Jun; 237(2):155-66. PubMed ID: 16084011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic interactions between Brca1 and Gadd45a in centrosome duplication, genetic stability, and neural tube closure.
    Wang X; Wang RH; Li W; Xu X; Hollander MC; Fornace AJ; Deng CX
    J Biol Chem; 2004 Jul; 279(28):29606-14. PubMed ID: 15123655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple‑negative breast cancer cells.
    Lee J; Gollahon L
    Int J Oncol; 2013 Mar; 42(3):839-47. PubMed ID: 23340795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEP135 isoform dysregulation promotes centrosome amplification in breast cancer cells.
    Ganapathi Sankaran D; Stemm-Wolf AJ; Pearson CG
    Mol Biol Cell; 2019 May; 30(10):1230-1244. PubMed ID: 30811267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamic recruitment of Nek2 kinase to the centrosome involves microtubules, PCM-1, and localized proteasomal degradation.
    Hames RS; Crookes RE; Straatman KR; Merdes A; Hayes MJ; Faragher AJ; Fry AM
    Mol Biol Cell; 2005 Apr; 16(4):1711-24. PubMed ID: 15659651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fanconi anemia complementation group A (FANCA) localizes to centrosomes and functions in the maintenance of centrosome integrity.
    Kim S; Hwang SK; Lee M; Kwak H; Son K; Yang J; Kim SH; Lee CH
    Int J Biochem Cell Biol; 2013 Sep; 45(9):1953-61. PubMed ID: 23806870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Nek2 protein kinase: a novel regulator of centrosome structure.
    Fry AM
    Oncogene; 2002 Sep; 21(40):6184-94. PubMed ID: 12214248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
    Araki K; Miyoshi Y
    Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.